Cutaneous neurofibromas are benign dermal tumors composed of spindle cells in a myxoid stroma containing numerous blood vessels. Here we describe 6 cases of solitary cutaneous neurofibroma showing unusually higher density of blood vessels in the stroma when compared to that of classical neurofibromas. We propose this lesion to be a new histopathological variant of neurofibroma and name it angioneurofibroma. © 2014 S. Karger AG, Basel

Neurofibromas are nonencapsulated, loosely textured dermal tumors composed of thin fascicles of cells with a spindle-shaped nucleus and scant cytoplasm [1]. The matrix is rich in mucin or sclerosing and hyalinized [2]. Blood vessels are increased in number in the stroma when compared to the normal skin, despite their white color in gross appearance [3]. Here we describe 6 cases of solitary cutaneous neurofibroma where the number of blood vessels in the stroma is unusually higher than that of classic neurofibromas.

Biopsy material obtained from 6 patients with solitary cutaneous neurofibromas diagnosed as ‘neurofibroma with a densely vascularized background' was reviewed and the number of blood vessels within the lesions was compared with 5 cases of solitary cutaneous neurofibroma showing a classical vascularized stroma.

The biopsy material was fixed in formalin, embedded in paraffin, cut at 5 µm and stained with hematoxylin-eosin, and immunohistochemistry was performed for S-100, CD34 and D2-40 according to standard procedures. We counted the number of blood vessels of each lesion per 10 high-power fields (×40) on anti-CD34-stained sections. Statistical analysis was performed by using an unpaired Student t test.

On histological examination, the well-known pattern of neurofibromas with an intact epidermis overlying a relatively ill-defined dermal proliferation of S-100-positive spindle cells with undulated nuclei in a collagenous background was observed in all of the cases (fig. 1). No atypia, mitosis or infiltrating pattern was observed. In the majority of the vessels, the endothelial cells showed a positive reaction pattern for CD34 (fig. 2c-d). There were also some vessels which were positive for D2-40, indicating their lymphatic origin (data not shown). The number of blood vessels was on average 50.7 (± 15.4) per 10 high-power fields (×40) in the cases of ‘neurofibroma with a densely vascularized background' whereas the average number of blood vessels counted was only 23.4 (± 7.2) in the classical neurofibromas (p < 0.005; unpaired Student t test; table 1; fig. 3).

Fig. 1

Angioneurofibroma [hematoxylin-eosin; original magnification: ×5 (a) and ×20 (c)] and classical neurofibroma [hematoxylin-eosin; original magnification: ×5 (b) and ×20 (d)].

Fig. 1

Angioneurofibroma [hematoxylin-eosin; original magnification: ×5 (a) and ×20 (c)] and classical neurofibroma [hematoxylin-eosin; original magnification: ×5 (b) and ×20 (d)].

Close modal
Fig. 2

S-100 immunostaining in angioneurofibroma (a; original magnification: ×20) and classical neurofibroma (b; original magnification: ×20); CD34 immunostaining in angioneurofibroma (c; original magnification: ×20) and classical neurofibroma (d; original magnification: ×20).

Fig. 2

S-100 immunostaining in angioneurofibroma (a; original magnification: ×20) and classical neurofibroma (b; original magnification: ×20); CD34 immunostaining in angioneurofibroma (c; original magnification: ×20) and classical neurofibroma (d; original magnification: ×20).

Close modal
Fig. 3

Number of vessels in the cases of angioneurofibroma (1-6, red diamonds) compared with that of the cases of classical neurofibroma (7-11, blue diamonds) (a); standard deviation of the number of vessels in 6 cases of angioneurofibroma compared with 5 cases of classical neurofibromas (b) (p < 0.005; unpaired Student t test).

Fig. 3

Number of vessels in the cases of angioneurofibroma (1-6, red diamonds) compared with that of the cases of classical neurofibroma (7-11, blue diamonds) (a); standard deviation of the number of vessels in 6 cases of angioneurofibroma compared with 5 cases of classical neurofibromas (b) (p < 0.005; unpaired Student t test).

Close modal

Neurofibromas are lesions characterized by delicate, in most cases only single cell-thick fascicles of cells with a spindled nucleus and scant cytoplasm [4], interpreted as Schwann cells on electron microscopy, and usually positive for S-100 protein [5]. The overlying epidermis is intact and separated from the lesion by a so-called dermal grenz zone. In some cases, an infiltrative pattern into the subcutis has been observed [1], and a vascularized stroma, sometimes abundant, has been documented [3]. In our cases, we were able to describe an unusually high vascular density compared not only with normal skin, but also with classical neurofibromas. In a series of neurofibromas from patients with neurofibromatosis-1 and sporadic neurofibromas, high vascular density associated with increased vascular endothelial growth factor immunoreactivity was shown [3]. This observation led to the suggestion that neurofibromas might have an angiogenic potential [3].

Megahed [1] described 10 histopathological variants of neurofibroma: classic, cellular, myxoid, hyalinized, epithelioid, plexiform, diffuse, pigmented, granular cell, and pacinian. Subsequently, some other variants such as dendritic cell neurofibroma with pseudorosettes [6] and lipomatous neurofibroma [7] have been reported. The histopathological pattern of the solitary cutaneous neurofibroma cases with a higher vascular density, which we describe here, is very particular. We therefore propose this lesion to be a new histopathological variant of neurofibroma and name it angioneurofibroma. Angioneurofibromas should be considered as a part of the morphological spectrum of neurofibromas. These lesions can be mixed histopathologically with vascular tumors. The gross appearance of angioneurofibromas should be compared to that of classical neurofibromas for any macroscopic difference. This feature might help to correctly interpret a highly vascularized lesion showing a histopathological pattern and immunohistochemical phenotype of neurofibroma, and to design new treatment strategies including angiogenesis inhibitors for these tumors.

1.
Megahed M: Histopathological variants of neurofibroma. A study of 114 lesions. Am J Dermatopathol 1994;16:486-495.
2.
Shek TWH: Sclerosing neurofibroma. Histopathology 2000;36:377-378.
3.
Arbiser JL, Flynn E, Barnhill RL: Analysis of vascularity of human neurofibromas. J Am Acad Dermatol 1998;38:950-954.
4.
Reed RJ, Fine RM, Meltzer HD: Palisaded, encapsulated neuromas of the skin. Arch Dermatol 1972;106:865-870.
5.
Waggener JD: Ultrastructure of benign peripheral nerve sheath tumors. Cancer 1966;19:699-709.
6.
Michal M, Fanburg-Smith JC, Mentzel T, Kutzner H, Requena L, Zamecnik M, Miettinen M: Dendritic cell neurofibroma with pseudorosettes: a report of 18 cases of a distinct and hitherto unrecognized neurofibroma variant. Am J Surg Pathol 2001;25:587-594.
7.
Val-Bernal JF, de sa Dehesa J, Garijo MF, Val D: Cutaneous lipomatous neurofibroma. Am J Dermatopathol 2002;24:246-250.
Open Access License / Drug Dosage / Disclaimer
Open Access License: This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial 3.0 Unported license (CC BY-NC) (www.karger.com/OA-license), applicable to the online version of the article only. Distribution permitted for non-commercial purposes only.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.